154 related articles for article (PubMed ID: 20679626)
1. Troponin I provides insight into cardiotoxicity and the anthracycline-trastuzumab interaction.
Ewer MS; Ewer SM
J Clin Oncol; 2010 Sep; 28(25):3901-4. PubMed ID: 20679626
[No Abstract] [Full Text] [Related]
2. Therapy Insight: anthracyclines and trastuzumab--the optimal management of cardiotoxic side effects.
Popat S; Smith IE
Nat Clin Pract Oncol; 2008 Jun; 5(6):324-35. PubMed ID: 18364726
[TBL] [Abstract][Full Text] [Related]
3. Adjuvant therapy for HER2 positive breast cancer: are anthracyclines still necessary?
Castrellon AB; Glück S
Clin Adv Hematol Oncol; 2008 Sep; 6(9):666-72. PubMed ID: 18827789
[TBL] [Abstract][Full Text] [Related]
4. Trastuzumab-related cardiotoxicity following anthracycline-based adjuvant chemotherapy: how worried should we be?
Morris PG; Hudis CA
J Clin Oncol; 2010 Jul; 28(21):3407-10. PubMed ID: 20530269
[No Abstract] [Full Text] [Related]
5. Re: Therapy Insight: anthracyclines and trastuzumab--the optimal management of cardiotoxic side effects.
Magné N; Chargari C
Nat Clin Pract Oncol; 2008 Nov; 5(11):E1. PubMed ID: 18957967
[No Abstract] [Full Text] [Related]
6. Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation.
Cardinale D; Colombo A; Torrisi R; Sandri MT; Civelli M; Salvatici M; Lamantia G; Colombo N; Cortinovis S; Dessanai MA; Nolè F; Veglia F; Cipolla CM
J Clin Oncol; 2010 Sep; 28(25):3910-6. PubMed ID: 20679614
[TBL] [Abstract][Full Text] [Related]
7. Reversibility of trastuzumab cardiotoxicity: is the concept alive and well?
Ewer MS; Tan-Chiu E
J Clin Oncol; 2007 Dec; 25(34):5532-3; author reply 5533-4. PubMed ID: 18048835
[No Abstract] [Full Text] [Related]
8. Anthracycline cardiotoxicity in breast cancer patients: synergism with trastuzumab and taxanes.
Gianni L; Salvatorelli E; Minotti G
Cardiovasc Toxicol; 2007; 7(2):67-71. PubMed ID: 17652806
[TBL] [Abstract][Full Text] [Related]
9. Trastuzumab-induced cardiotoxicity: is it time for troponin for all patients?
Ferté C; Massard C; Cohen A; Soria JC; Ederhy S
Am J Clin Oncol; 2012 Apr; 35(2):183-4. PubMed ID: 22433996
[No Abstract] [Full Text] [Related]
10. Population pharmacokinetic-pharmacodynamic analysis of trastuzumab-associated cardiotoxicity.
van Hasselt JG; Boekhout AH; Beijnen JH; Schellens JH; Huitema AD
Clin Pharmacol Ther; 2011 Jul; 90(1):126-32. PubMed ID: 21633346
[TBL] [Abstract][Full Text] [Related]
11. Cardiotoxicity associated with the use of trastuzumab in breast cancer patients.
Perik PJ; de Korte MA; van Veldhuisen DJ; Gietema JA; Sleijfer DT; de Vries EG
Expert Rev Anticancer Ther; 2007 Dec; 7(12):1763-71. PubMed ID: 18062750
[TBL] [Abstract][Full Text] [Related]
12. Chemotherapy-induced cardiotoxicity in women.
Dempsey KS
Crit Care Nurs Clin North Am; 2008 Sep; 20(3):343-50. PubMed ID: 18644518
[TBL] [Abstract][Full Text] [Related]
13. Never use anthracyclines with trastuzumab: it is time to reconsider the taboo.
Gianni L
Breast Cancer Res Treat; 2009 Oct; 117(3):599-601. PubMed ID: 19387827
[No Abstract] [Full Text] [Related]
14. Trastuzumab-associated cardiotoxicity.
Keefe DL
Cancer; 2002 Oct; 95(7):1592-600. PubMed ID: 12237930
[TBL] [Abstract][Full Text] [Related]
15. 111Indium-trastuzumab visualises myocardial human epidermal growth factor receptor 2 expression shortly after anthracycline treatment but not during heart failure: a clue to uncover the mechanisms of trastuzumab-related cardiotoxicity.
de Korte MA; de Vries EG; Lub-de Hooge MN; Jager PL; Gietema JA; van der Graaf WT; Sluiter WJ; van Veldhuisen DJ; Suter TM; Sleijfer DT; Perik PJ
Eur J Cancer; 2007 Sep; 43(14):2046-51. PubMed ID: 17719768
[TBL] [Abstract][Full Text] [Related]
16. Cardiac risks in multimodal breast cancer treatment.
Budach W
Strahlenther Onkol; 2007 Dec; 183 Spec No 2():9-10. PubMed ID: 18166997
[No Abstract] [Full Text] [Related]
17. Trastuzumab-related cardiac dysfunction.
Telli ML; Witteles RM
J Natl Compr Canc Netw; 2011 Feb; 9(2):243-9. PubMed ID: 21310845
[TBL] [Abstract][Full Text] [Related]
18. Cardiotoxicity associated with trastuzumab treatment of HER2+ breast cancer.
Fiúza M
Adv Ther; 2009 Jul; 26 Suppl 1():S9-17. PubMed ID: 19669637
[TBL] [Abstract][Full Text] [Related]
19. Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment.
Ewer MS; Vooletich MT; Durand JB; Woods ML; Davis JR; Valero V; Lenihan DJ
J Clin Oncol; 2005 Nov; 23(31):7820-6. PubMed ID: 16258084
[TBL] [Abstract][Full Text] [Related]
20. Anthracyclines and trastuzumab; getting to the heart of the matter: when getting to the heart is the matter.
Morris PG; Hudis CA
Breast Cancer Res Treat; 2011 Jun; 127(2):585-6. PubMed ID: 18791822
[No Abstract] [Full Text] [Related]
[Next] [New Search]
